The use of RAAS inhibitors, such as renin inhibitors, Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin Receptor Blockers (ARBs), and mineralocorticoid receptor antagonists has been documented to prevent fibrosis and slow the decline of organ function effectively in the process of kidney disease and cardiac hypertrophy (Zhang et al., 2019a). This evidence concerns the gene ACE and kidney disorder.